Myeloma Paper of the Day, July 4th, suggested by Robert Orlowski
Robert Orlowski shared a post on X:
“Myeloma Paper of the Day: Patients with t(11;14) AL (amyloidosis) who progress or have an inadequate response on Darzalex therapy have excellent responses to venetoclax with hematologic response rate 97%, and excellent organ responses (74% in cardiac, 46% in renal).”
Source: Robert Orlowski/X
Authors: Danai Dima, Michael Hughes, Mark Orland, Fauzia Ullah, Utkarsh Goel, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Divaya Bhutani, Louis Williams, Suzanne Lentzsch, Christy Samaras, Jason Valent, Rajshekhar Chakraborty and Jack Khouri.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
